Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study
NCT ID: NCT00510380
Last Updated: 2009-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2007-04-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Intrauterine fetal programming is effected through epigenetic changes similar to those previously identified in animal studies. The epigenetic markers can be found in growth restricted Chinese pregnancies in the local population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
NCT03398629
Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)
NCT06096805
The National Standard for Normal Fetal Growth
NCT00912132
Environmental Factors and Embryonic Development Project
NCT04182503
EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
NCT01490489
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to determine if epigenetic markers of the metabolic syndrome are present in selected Chinese pregnancies in Singapore.
Hypothesis:
Intrauterine fetal programming is effected through epigenetic changes similar to those previously identified in animal studies. The epigenetic markers can be found in growth restricted Chinese pregnancies in the local population.
Methodology Umbilical cords and cord blood will be collected from twenty unequivocally growth-restricted Chinese pregnancies and twenty appropriately-grown Chinese pregnancies. DNA extracted from these tissues will be subjected to a custom-made DNA methylation array probing for specific changes in 262 candidate genes important to fetal endocrine and metabolic control.
This will be done using either a methylation array or a Sequenorn 2 in the DNA extracts that have been identified through Epigen academic consortium of the Liggins Institute and UK collaborators.
Anthropometric data will be collected from the infants at birth, and subsequently at 3,6,12,18 and 24 months and we will seek differential measures of programming.
Application The discovery of biomarkers indicating shifted developmental trajectories is the most important need in developmental programming research. Birth weight alone is not a valid measure. Biomarkers predictive of later obesity and the metabolic syndrome will be invaluable in formulating preventive strategies for these diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
growth-restricted Chinese pregnancies
No interventions assigned to this group
appropriately-grown Chinese pregnancies
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Singleton pregnancies,
3. fetal growth restriction diagnosed clinically and by ultrasound parameters,
4. Normally grown fetuses by clinical and ultrasound criteria
Exclusion Criteria
2. Multiple pregnancies
3. Co-existing antenatal complications including sever pre-eclampsia
21 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University Hospital, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
National University Hospital, Singapore
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yap Seng Chong, MBBS
Role: PRINCIPAL_INVESTIGATOR
National University Hospital, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National University Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIG/07072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.